局部放疗联合化疗对比单纯化疗治疗初诊转移性鼻咽癌的疗效与安全性:多中心3期随机临床试验
该多中心3期随机临床试验纳入126例化疗敏感的初诊转移性鼻咽癌患者,随机接受化疗联合放疗或单纯化疗。
要点
- 化疗联合局部放疗显著改善初诊转移性鼻咽癌患者的总生存期。
- 联合放疗组24个月总生存率为76.4%,单纯化疗组为54.5%。
- 联合放疗组急性3级及以上皮炎、黏膜炎和口干发生率分别为8.1%、33.9%和6.5%。
核心结论
- 在化疗敏感的初诊转移性鼻咽癌患者中,化疗联合局部放疗较单纯化疗显著改善总生存期。
研究设计与样本
- 多中心3期随机临床试验,纳入126例经3周期顺铂和氟尿嘧啶化疗后达到完全或部分缓解的初诊转移性鼻咽癌患者,1:1随机分配至化疗联合放疗组(n=63)或单纯化疗组(n=63)。
- 中位随访时间为26.7个月(IQR 17.2-33.5)。
主要发现
- 化疗联合放疗组24个月总生存率为76.4%(95%CI 64.4%-88.4%),单纯化疗组为54.5%(95%CI 41.0%-68.0%)。
- 无进展生存期分层HR为0.36(95%CI 0.23-0.57),支持化疗联合放疗。
- 两组急性血液学或胃肠道毒性无显著差异。
- 化疗联合放疗组急性3级及以上皮炎、黏膜炎和口干发生率分别为8.1%、33.9%和6.5%;晚期严重3级及以上听力损失和牙关紧闭发生率分别为5.2%和3.4%。
关键数值与推荐
- 化疗方案为氟尿嘧啶5 g/m²持续静脉输注120小时,第1天顺铂100 mg/m²静脉注射,每3周一次,共6周期。
- 化疗联合放疗组在化疗后接受调强放疗(IMRT)。
临床怎么用
- 对于经3周期顺铂和氟尿嘧啶化疗后达到完全或部分缓解的初诊转移性鼻咽癌患者,可考虑在化疗基础上加用局部调强放疗以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear. OBJECTIVE: To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC. DESIGN, SETTING, AND PARTICIPANTS: Patients with biopsy-proven mNPC, who demonstrated complete or partial response (RECIST v1.1) following 3 cycles of cisplatin and fluorouracil chemotherapy, were enrolled. Eligible patients were randomly assigned (1:1) to receive either chemotherapy plus radiotherapy or chemotherapy alone. Overall, 126 of 173 patients screened were eligible to the study, and randomized to chemotherapy plus radiotherapy (n = 63) or chemotherapy alone (n = 63). Median (IQR) follow-up duration was 26.7 (17.2-33.5) months. INTERVENTIONS: The chemotherapy regimens were fluorouracil continuous intravenous infusion at 5 g/m2 over 120 hours and 100 mg/m2 intravenous cisplatin on day 1, administered every 3 weeks for 6 cycles. Patients assigned to the chemotherapy plus radiotherapy group received intensity-modulated radiotherapy (IMRT) after chemotherapy. MAIN OUTCOMES AND MEASURES: The primary end point of the study was overall survival (OS). The secondary end point was progression-free survival (PFS) and safety. RESULTS: Overall, 126 patients were enrolled (105 men [83.3%] and 21 women [16.7%]; median [IQR] age, 46 [39-52] years). The 24-month OS was 76.4% (95% CI, 64.4%-88.4%) in the chemotherapy plus radiotherapy group, compared with 54.5% (95% CI, 41.0%-68.0%) in the chemotherapy-alone group. The study met its primary end point of improved OS (stratified hazard ratio [HR], 0.42; 95% CI, 0.23-0.77; P = .004) in favor of chemotherapy plus radiotherapy. Progression-free survival was also improved in the chemotherapy plus radiotherapy group compared with the chemotherapy-alone group (stratified HR, 0.36; 95% CI, 0.23-0.57). No significant differences in acute hematological or gastrointestinal toxic effects were observed between the treatment arms. The frequency of acute grade 3 or higher dermatitis, mucositis, and xerostomia was 8.1%, 33.9%, and 6.5%, respectively, in the chemotherapy plus radiotherapy group. The frequency of late severe grade 3 or higher hearing loss and trismus was 5.2% and 3.4%, respectively, in the chemotherapy plus radiotherapy group. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, radiotherapy added to chemotherapy significantly improved OS in chemotherapy-sensitive patients with mNPC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02111460.
引用
- You R, Liu YP, Huang PY, et al. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32701129. doi:10.1001/jamaoncol.2020.1808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。